Abstract: Disclosed is a method for preparing high-load oral paclitaxel capsule for a slow release in colon, belonging to the field of porous starch drug loading. The preparation method of the present disclosure includes the following steps: (1) dripping an ethanol solution of paclitaxel into a water phase and drying the solution to obtain an amorphous paclitaxel microsphere; (2) redissolving the paclitaxel microsphere prepared in step (1) in the ethanol solution, dispersing porous starch in the ethanol solution for adsorption, volatilizing a solvent in an oven, washing the porous starch with the ethanol solution to remove unadsorbed paclitaxel, and centrifuging same to obtain a precipitate, namely the porous starch loaded with paclitaxel; and (3) dispersing the porous starch loaded with paclitaxel prepared in step (2) in a chitosan solution, dropwise adding the solution into a phytic acid solution, and stirring the solution for 4 hours to obtain a coated capsule.

Abstract: Disclosed is a method for preparing high-load oral paclitaxel capsule for a slow release in colon, belonging to the field of porous starch drug loading. The preparation method of the present disclosure includes the following steps: (1) dripping an ethanol solution of paclitaxel into a water phase and drying the solution to obtain an amorphous paclitaxel microsphere; (2) redissolving the paclitaxel microsphere prepared in step (1) in the ethanol solution, dispersing porous starch in the ethanol solution for adsorption, volatilizing a solvent in an oven, washing the porous starch with the ethanol solution to remove unadsorbed paclitaxel, and centrifuging same to obtain a precipitate, namely the porous starch loaded with paclitaxel; and (3) dispersing the porous starch loaded with paclitaxel prepared in step (2) in a chitosan solution, dropwise adding the solution into a phytic acid solution, and stirring the solution for 4 hours to obtain a coated capsule.

Abstract: The disclosure pertains to single chain antibodies, nucleic acids and vectors that encode antibodies that for example specifically bind W68 in the context of DAGWGNL (SEQ ID NO: 1) and methods of administering the single chain antibodies, nucleic acids and vectors to a subject in need thereof.

Abstract: Disclosed herein are oligomeric compounds such as antisense oligonucleotides, siRNA and shRNAs and compositions for knocking down human RACK1, and methods for treating a TDP43-opathy or a FUS-opathy neurodegenerative disease optionally selected from amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), frontotemporal lobar dementia (FTLD), Huntington's disease (HD), neuronal intermediate filament inclusion disease (NIFID), basophilic inclusion body disease (BIBD) or limbic-predominant age-related TDP-43 encephalopathy (LATE) in a subject in need thereof or for reducing TDP-43 and/or FUS aggregation in a cell, the methods comprising administering to the subject in need thereof or introducing into the cell one or more antisense molecule(s) targeting RACK1, optionally one or more oligomeric compound disclosed herein.